Denosumab: The Better Option for Bone Metastases in NSCLC?Denosumab: The Better Option for Bone Metastases in NSCLC?
Dr. Jack West discusses data indicating that denosumab is superior to zoledronic acid in reducing skeletal complications and increasing overall survival in lung cancer patients with bone metastases. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2013 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news
Post hoc analysis: Reduction in risk of clinical fractures after a single dose of zoledronic acid
Source: Journal of Clinical Endocrinology and Metabolism
Area: News
Annual infusions of zoledronic acid 5 mg over 3 years have been shown to produce stable reductions in biochemical markers of bone turnover, have sustained increases in bone mineral density (BMD), and reduce the incidence of vertebral, hip, and nonvertebral fractures compared with placebo in women with postmenopausal osteoporosis. More recently, data regarding the duration of effect of single doses of zoledronic acid on BMD and markers of bone turnover have raised the question of whether zoledronic acid administration at intervals of longer than 1 year res...
Source: NeLM - News - January 18, 2013 Category: Drugs & Pharmacology Source Type: news
